EXCITING! .... Volunteer now for Phase 3 Study!

[PDWarrior1900]

Phase 3 Trial now recruiting for AnnovisBio.com

"Buntanetap (previously known as ANVS401 or Posiphen) is our lead compound. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Different from monoclonal antibody therapies, buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once."

"Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases. Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It’s being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome."

"The compound was tested in three Phase 1 and two Phase 2 clinical studies that show it is well tolerated. In the two Phase 2 clinical studies buntanetap showed efficacy in AD and PD patients. buntanetap-treated PD patients showed statistically significant improvements in both the speed and the accuracy of execution in the WAIS Coding Scale and MDS-UPDRS test."

"Buntanetap is the only drug so far to show improvement in cognition in AD patients and motor function in PD patients."

Protocol Number:

ANVS-22001

Protocol Title:

A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of Buntanetap or Placebo in patients with early Parkinson’s disease

Doses:

0 (placebo), 10 and 20 mg per day

Inclusion Criteria:

Hohn & Yahr in off stage 1, 2 or 3

OFF stage < 2 hours per day

We will start a phase 3 in advanced PD with OFF stage >2 hours next year

----------------------------------------------------------------------------------------------------------------

There are over 40 USA clinical trial sites.

The excel file below has the location and contact person for your enrollment.

Download the excel list here:

docs.google.com/spreadsheet...

[jrg54321]

No sites in Massachusetts.

[LauraYu]

Sadly they don’t have a site in Canada. Otherwise I would volunteer right away

[PDWarrior1900]

GREAT UPDATE from the president of AnnovisBio.com !!!------------------------------------------------------------------------------

I've been exchanging emails with the president of the company...

I just got her email this morning on august 31, 2022 ...

---------------------------------------------------------------------

"The history of the drug you read is another drug, phenserine, that failed in phase 3. The drug we are developing is an analog of phenserine that has totally different activity from phenserine."

"Because it came from the same company and the structures look similar, very often people confuse the two Posiphen is NOT phenserine, it has never failed, and it inhibits the translation of multiple neurotoxic proteins. Phenserine is an ACHEI like Aricept, Posiphen has NO ACHEI activity"

Best

Maria

-------------------------------------------------------------------------------

If you can, I highly encourage everyone to volunteer for this phase 3 study (it's an oral med).